Articles and Resources

Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma

This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) August 2006

Sponsors and Collaborators:

Case Comprehensive Cancer Center

National Cancer Institute (NCI)

Information provided by:

National Cancer Institute (NCI) Identifier:



RATIONALE: Drugs used in chemotherapy, such as methotrexate, vinorelbine, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells. Cisplatin may also make tumor cells more sensitive to radiation therapy. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy with or without surgery and chemoradiotherapy works in treating patients with malignant pleural mesothelioma.




Localized Malignant Mesothelioma
Sarcomatous Mesothelioma
Advanced Malignant Mesothelioma
Epithelial Mesothelioma

 Drug: cisplatin
 Drug: methotrexate
 Drug: vinorelbine ditartrate
 Procedure: adjuvant therapy
 Procedure: chemotherapy
 Procedure: conformal radiation therapy
 Procedure: conventional surgery
 Procedure: intensity-modulated radiation therapy
 Procedure: neoadjuvant therapy
 Procedure: radiation therapy
 Procedure: radiosensitization
 Procedure: surgery

Phase II

MedlinePlus related topics:  Cancer;   Cancer Alternative Therapies;   Mesothelioma
Genetics Home Reference related topics:  Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Induction Combination Chemotherapy Comprising Methotrexate, Vinorelbine Ditartrate, and Cisplatin With or Without Surgery and Adjuvant Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Further study details as provided by National Cancer Institute (NCI):



  • Assess the response to induction combination chemotherapy comprising methotrexate, vinorelbine ditartrate, and cisplatin in patients with previously untreated malignant pleural mesothelioma.


  • Assess the tolerability and toxicity of this regimen in these patients.

  • Determine relapse-free and overall survival of patients treated with induction combination chemotherapy with or without surgery and hemithoracic radiation.

  • Assess the impact of induction combination chemotherapy on operability and surgical success.

  • Evaluate the impact of these treatment regimens on quality of life.


  • Induction chemotherapy: Patients receive MVP chemotherapy comprising cisplatin IV over 30-60 minutes on day 1 and vinorelbine ditartrate IV over 5-10 minutes and methotrexate IV over 5-30 minutes on days 8, 15, and 22. Treatment repeats every 28 days for 2 courses. Patients with unresectable disease may receive up to 2 additional courses of induction chemotherapy. Patients requiring palliative radiotherapy or who have progressive disease are removed from the study. Patients with resectable disease or sarcomatoid histology and T1-3, N1-2 disease with a complete or partial response to induction chemotherapy proceed to surgery.

  • Surgery: Patients with extensive disease undergo palliative debulking pleurectomy and decortication and then are taken off study. All other patients undergo a thoracotomy with an extrapleural pneumonectomy and then proceed to chemoradiotherapy.

  • Chemoradiotherapy: Beginning 6-10 weeks after surgery, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients also receive cisplatin IV over 30-60 minutes on days 1 and 22. Patients with responding disease proceed to adjuvant chemotherapy.

  • Adjuvant chemotherapy: Patients receive 2 additional courses of MVP chemotherapy as above.

Quality of life is assessed at baseline, after each course of induction chemotherapy, before surgery, and then every 3 months thereafter.

After completion of study therapy, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.


Ages Eligible for Study:  up to  75 Years,  Genders Eligible for Study:  Both



  • Histologically confirmed malignant pleural mesothelioma

  • Amenable to aggressive surgical resection, if deemed resectable

  • Patients with potentially resectable disease must have undergone mediastinoscopy to establish surgical stage

  • Resectable disease is defined as any of the following:

  • Epithelioid, mixed histology, or histology not otherwise specified with clinical stage I-III (T1-3, N0-2, M0) disease

  • Sarcomatoid histology with clinical stage I-III (T1-3, N0) disease

  • Intraperitoneal extension, contralateral thoracic extension, or distant metastases are eligible, but considered unresectable

  • Disease considered unresectable by any medical reason or if surgery was declined


  • ECOG performance status 0-1

  • WBC ≥ 3,000/mm³

  • Platelet count > 100,000/mm³

  • Creatinine ≤ 1.7 mg/dL

  • Alkaline phosphatase < 2 times normal

  • AST < 2 times normal

  • Albumin > 3 g/dL

  • Bilirubin < 2.0 mg/dL

  • Patients must be available for and compliant with adequate long-term follow-up

  • Not pregnant

  • Negative pregnancy test

  • Fertile patients must use effective contraception

  • Patients with resectable disease must have adequate pulmonary function to undergo surgery and radiotherapy

  • No other active malignancies


  • No prior surgical resection, radiation therapy, chemotherapy, or immunotherapy for this cancer

Location and Contact Information

Please refer to this study by identifier  NCT00354393

      Case Comprehensive Cancer Center, Cleveland,  Ohio,  44106-5065,  United States; Recruiting
      David J. Adelstein, MD  216-444-9310 

Study chairs or principal investigators

      David J. Adelstein, MD,  Study Chair,  Case Comprehensive Cancer Center   

More Information

Study ID Numbers:  CDR0000486304; CASE-CCF-IRB-5179; CASE-CCF-0755
Last Updated:  September 6, 2006
Record first received:  July 19, 2006 Identifier:  NCT00354393
Health Authority: United States: Federal Government processed this record on 2006-09-14